Sequence-Specific Targeting of Dosage Compensation in Drosophila Favors an Active Chromatin Context

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Sequence-Specific Targeting of Dosage Compensation in Drosophila Favors an Active Chromatin Context

Artym A. Alekseyenko, Joshua W. K. Ho, Shouyong Peng, Marnie Gelbart, Michael Y. Tolstorukov, Annette Plachetka, Peter V. Kharchenko, Youngsook L. Jung, Andrey A. Gorchakov, Erica Larschan, Tingting Gu, Aki Minoda, Nicole C. Riddle, Yuri B. Schwartz, Sarah C. R. Elgin, Gary H. Karpen, Vincenzo Pirrotta, Mitzi I. Kuroda, Peter J. Park

Abstract

The Drosophila MSL complex mediates dosage compensation by increasing transcription of the single X chromosome in males approximately two-fold. This is accomplished through recognition of the X chromosome and subsequent acetylation of histone H4K16 on X-linked genes. Initial binding to the X is thought to occur at “entry sites” that contain a consensus sequence motif (“MSL recognition element” or MRE). However, this motif is only ∼2 fold enriched on X, and only a fraction of the motifs on X are initially targeted. Here we ask whether chromatin context could distinguish between utilized and non-utilized copies of the motif, by comparing their relative enrichment for histone modifications and chromosomal proteins mapped in the modENCODE project. Through a comparative analysis of the chromatin features in male S2 cells (which contain MSL complex) and female Kc cells (which lack the complex), we find that the presence of active chromatin modifications, together with an elevated local GC content in the surrounding sequences, has strong predictive value for functional MSL entry sites, independent of MSL binding. We tested these sites for function in Kc cells by RNAi knockdown of Sxl, resulting in induction of MSL complex. We show that ectopic MSL expression in Kc cells leads to H4K16 acetylation around these sites and a relative increase in X chromosome transcription. Collectively, our results support a model in which a pre-existing active chromatin environment, coincident with H3K36me3, contributes to MSL entry site selection. The consequences of MSL targeting of the male X chromosome include increase in nucleosome lability, enrichment for H4K16 acetylation and JIL-1 kinase, and depletion of linker histone H1 on active X-linked genes. Our analysis can serve as a model for identifying chromatin and local sequence features that may contribute to selection of functional protein binding sites in the genome.

Introduction

In Drosophila, Male Specific Lethal (MSL) complex binds to the single male X chromosome to increase transcription approximately two-fold, in order to equalize the output of both female X chromosomes [2–4]. We have proposed that MSL complex locates its target binding sites using a two-step mechanism [5]. First, the complex distinguishes X from autosomes by binding a subset of 200–300 sites on X known as “chromatin entry sites” (CES) [6–8] or “high affinity sites” (HAS) [9,10]. Recognition of CES is a sequence-dependent step, as these sites share a GA-rich motif [8,10] designated the “MSL recognition element”, or MRE, whose function has been demonstrated by site-directed mutagenesis [8]. In contrast, the second targeting step lacks a consensus sequence but is strongly linked to transcription [11–14], with the complex locating active genes on the same chromosome [15].

CES were first identified in msl3 mutant embryos, in which the initial, sequence-specific step of MSL binding occurs but the second, sequence-independent step does not [7,8]. The MRE sequence motif was discovered based on the first 150 mapped CES [8,10]. Recognition of CES is a sequence-dependent step, as these sites share a GA-rich motif...
be dependent upon the intact MRE motif [8]. 150 is likely an underestimate of the total number of CES and functional MREs on X, as subsequent analysis of high occupancy MSL binding sites in wild type cells has revealed 309 peaks containing 379 MREs [8]. However, a conservative set of 150 should be sufficient to test for predictive features.

The MRE motif is only modestly enriched on the X chromosome compared to the autosomes. At a stringency where 157 of 150 CES contain the consensus motif (p-value of 10\(^{-5}\)), there is a 1.8 fold higher MRE density on X compared to autosomes (on average 1 per 6 Kb on X, and 1 per 11 Kb on autosomes; Figure S1A), [8]. These average densities correspond to 12,481 total MREs in the genome, of which only 1 in 91 correspond to the set of CES considered here. Even if we restrict our attention to chromosome X, only 1 in 28 MREs map to the CES set. Therefore, a key question is how functional MREs within CES are somehow recognized among the vast excess of un-utilized sites. That the MSL complex targets only a fraction of potential MRE sites for initial binding is a characteristic it shares with many sequence-specific binding factors whose predicted target motifs are often in vast excess to the sites actually utilized [16,17]. Here, we investigate whether chromatin features influence binding site selection, using the MSL complex and a large compendium of genome-wide ChIP-chip profiles generated by the NHGRI modENCODE project as a model [18]. Our results support a model in which active chromatin composition and intrinsic GC content help define the initial binding sites of the MSL complex.

Results

An active chromatin context is predictive of functional MREs

To search for chromatin features that can distinguish functional MREs from those that do not recruit MSL complex [i.e., non-functional MREs], we defined five classes of MREs in the Drosophila genome. The first set consists of 137 MREs that were experimentally defined by MSL complex binding [8], as discussed above. We called this set “Functional MREs”. The remaining four sets of 150 sequences each consist of the MREs that have the best consensus motif matches on either X or a control autosomal arm (2L) (“Best on X” and “Best on 2L” respectively, and 150 MREs chosen at random from either X or 2L (“Random X” and “Random 2L” respectively). We note that, in general, functional MREs display a broad range of motif binding specificity rather than being the best matches to the MRE consensus motif (Figure S1B). The result of this analysis is not affected by the choice of chromosome arm or the choice of random MREs (data not shown).

In each of the five classes of MREs, their locations are distributed along the length of the chromosome arm with no obvious clustering (Figure S1C). Within each set of sequences, we compared the average profiles of various chromatin marks mapped by the modENCODE Drosophila Chromatin Consortium using genome-wide ChIP-chip. The average ChIP enrichment profiles for 10 kb regions centered around the motif in two male cell lines (S2 and BG3) are shown in Figure 1B–1C. We found that a number of chromatin marks associated with active transcription are strikingly enriched near functional MREs in CES, and not in the best or random MRE classes on X or autosomes. These include RNA pol II, H3K36me3, H3K9ac, and H2B-ubiquitin. In addition, functional sites are relatively depleted for core histone H4 and linker histone H1. Consistent binding of the sequence-dependent GAGA factor [19] across categories serves as an important control to demonstrate that GA-rich elements are broadly represented in each group of MREs. Another notable feature of these profiles is the enhancement of H4K16ac on the X chromosome as a whole [20–22], with additional enrichment of H4K16ac on true CES (Figure 1B–1C). Since enrichment of H4K16 acetylation is a known consequence of MSL targeting, we proceeded to ask whether the observed difference in chromatin context for other chromatin marks at CES might simply be a consequence of MSL binding rather than a contributing factor.

Predictive chromatin marks are independent of MSL binding

To test whether the observed difference in chromatin context at CES is a consequence of MSL binding rather than a contributing factor, we examined the profiles of the same subset of chromatin marks in female Kc cells. Interestingly, we found that the set of marks that correlates with MRE function in male S2 cells were likewise informative in female Kc cells, in the absence of MSL complex (Figure 1D). The enrichment of H4K16 acetylation on the male X is notably less pronounced in female Kc cells lacking MSL complex. Still, this mark is enriched over functional MREs, consistent with previous observations of MSL-independent H4K16 acetylation at active genes on all chromosomes in males and females [21,22]. Most strikingly, H3K36me3 and JIL-1, are enriched in functional MREs in both male and female cells, suggesting that these marks are independent of MSL binding at CES.

We also examined MREs for intrinsic sequence composition to search for correlations with function (Figure 1E). Surprisingly, we found a marked elevation of GC content in the 10 Kb flanking region surrounding functional MREs, coupled with a decrease in GC content in the 1 Kb nearest the functional MREs. Taken together, our results support a model in which local sequence characteristics and the active chromatin context of functional MREs may facilitate their initial selection.

Next, we wanted to directly test the potential of MREs in an active chromatin environment in females to recruit MSL complex. The key female sex determination protein, SXL, represses dosage compensation by inhibiting MSL2 translation [23,24]. Loss of SXL results in the expression, stabilization, and targeting of the
MSL complex in female cells [25]. Therefore, we depleted SXL by RNA interference (RNAi) in Kc cells [26]. Upon treatment, we observed a general, MSL2-dependent increase in transcription from the female X chromosomes, consistent with a partial induction of dosage compensation (Figure 2A–2B). The increase in X-linked gene expression did not reach the maximum theoretical amount for perfect compensation ($\log_2 2 = 1$), consistent with observations that MSL-independent ploidy effects can also contribute to overall compensation [27,28].

The induction of MSL complex in Kc cells allowed us to ask whether ectopic MSL complex in female cells recognized the same functional subset of MREs on X as in male cells, by examining the distribution of H4K16 acetylation as a mark of MSL function. We found that Sxl RNAi induces high levels of this modification preferentially at the same MREs that are functional in males (Figure 2C), supporting the idea that MSL complex recognizes MREs in an active chromatin context. Our findings with MSL complex parallel recent results for the heat shock transcription factor HSF [29], suggesting that sequence-specific DNA binding factors may generally utilize chromatin context to facilitate selective targeting within a complex eukaryotic genome.

**Figure 1.** Active chromatin context and elevated GC content are associated with functional MSL recognition elements (MREs) on the X chromosome, independent of MSL binding. (A) The sequence motif for the MRE. (B–D) The average enrichment of various chromatin modifications or chromatin-binding proteins around (+/− 5 kb) the functional and non-functional MREs is visualized using a heat map in each of three *Drosophila* cell lines: S2 in panel B; BG3 in panel C; and Kc in panel D. (E) A heat map showing the average GC content around each class of MREs. The data were obtained from genome-wide ChIP-chip profiles generated as part of the modENCODE project. Many active marks are broadly enriched around functional MREs in both male and female cell lines, suggesting that active chromatin is strongly associated with functional MREs independent of MSL binding. See also Figures S1 and S2.

doi:10.1371/journal.pgen.1002646.g001
Identification of the best chromatin marks for prediction of functional MREs

Since specific chromatin marks are enriched near MREs that are utilized compared with those that are not, we next asked whether these marks provide enough information, either individually or in combination, to explain the MSL entry site binding pattern on X. To address this question, we systematically investigated the predictive power of the chromatin marks for functional MREs in Kc cells, which have the potential for MSL targeting but do not express the MSL complex. We asked whether we could build a simple prediction model based on individual or a combinations of chromatin features in Kc cells that would distinguish functional MREs from non-functional ones in male S2 and BG3 cells, where MSL complex is expressed.

We first tested whether individual chromatin features could discriminate functional MREs from non-functional ones. A chromatin feature is defined by its average ChIP enrichment within the 10 kb region surrounding each MRE. In addition, we defined two features to represent the average GC content near the MRE (center 1 kb) or in its flanking regions (10 kb excluding the center 1 kb). To test whether individual or combinations of features could distinguish the functional MREs from the non-functional ones, we used support vector machine (SVM), a classification algorithm demonstrated to have excellent performance in a wide range of problems [30,31]. Briefly, the set of ChIP enrichment at each MRE is treated as a feature vector of that MRE. Given a set of training samples, SVM calculates an optimal hyperplane that can separate non-functional MREs from functional MREs in the feature space. Here we used a SVM with a radial basis kernel that is implemented in the R package e1071 (See Methods and Materials). To accurately estimate predictive power, and to avoid the potential bias due to using the same set of CES and non-functional MRE genomic locations in S2, BG3 and Kc cell lines, we evaluated the predictive power of a feature using 10-fold cross-validation. In this scheme, we withhold a random 10% of the MREs, build a model based on the remaining 90%, measure how well the model predicted the functionality of the withheld MREs, and repeat this process multiple times to obtain the average performance. The cross-validation result is presented using a standard measure called the Area Under Curve (AUC) of Receiver Operating Characteristic [32] curve. The ROC curve (examples are shown in Figure 3C) quantifies the sensitivity and specificity of classification by estimating true and false positive rates over all threshold values, and the AUC summarizes the curve with a single number. A random predictor receives an AUC of 0.5, and a perfect predictor achieves an AUC of 1 [32].

By comparing the AUC of each individual chromatin feature in Kc, S2 and BG3 cells, we observed that many active chromatin marks could distinguish functional from non-functional MREs (Figure 3A). Among all the features tested, H3K36me3 was the best predictor in all three cell lines (mean AUC of 0.884), followed by JIL-1 (mean AUC of 0.864). Interestingly, we had previously speculated that H3K36me3 might be involved, based on MSL affinity for this mark in active genes [8,12,14]. Since H3K36me3
and JIL-1 are enriched in Kc cells at predicted CES even without MSL binding, they could prime functional MREs for sequence-specific MSL binding, or be coincident with true causative factors. Nearly all putative CES in Kc cells are embedded in a chromatin environment enriched for H3K36me3 (Figure 3B); however, we previously determined that when H3K36me3 is depleted, there are still enough features for the MSL complex to distinguish MREs [12]. Since no single feature may be sufficient to drive MSL recognition, we next asked whether combinations of marks and local sequence composition might further improve predictive power for CES.

Predictions utilizing combinations of chromatin marks and local GC content

On average, the GC content of CES is similar to the random or best MREs in the 1 Kb of sequence immediately surrounding the motif, but the GC content consistently rises in flanking sequences, to produce a distinctive average profile (Figure 1E). Examination of the individual heatmaps confirms that this is a broadly consistent characteristic of CES (Figure S2). We found that the relative GC content in D. melanogaster is elevated in genes compared to intergenic sequence (44% vs. 41%) [33] so it is not surprising to see this characteristic in conjunction with the active gene clusters where CES are found. However, the distinctive shape of the profile, with low GC immediately surrounding the CES, is unexpected and not seen with autosomal MREs, even when associated with H3K36me3 and thus presumably analogous active gene clusters (Figure S2). The significance of this intrinsic feature clearly merits future experimental analysis. However, GC profile alone does not appear to provide enough information to predict functional MREs with high accuracy (Figure 3C).

To search for combinatorial marks that might distinguish functional MREs, we compared the predictive power of the SVM generated using every possible combination of features in our dataset (Figure S3A–S3B). We found that the best individual features (H3K36me3 and JIL-1) performed very well, similarly to the best combinations of features when SVM trained using Kc data, and tested on S2 or BG3 data (Figure 3C). There are many combinations of features that predict functional MREs with high accuracy. In general, the best performing combinations included the following: (1) H3K36me3 or JIL-1; (2) H2B-ubiq or H3K9ac; (3) a core histone; and (4) GC content (Figure S3A–S3B). The excellent performance of this combination is consistent with the identification of these factors as core features by feature correlation analysis (Figure S3C).

The cross-validation results are summarized in the ROC plots in Figure 3C and Figure S3D. Although not perfect, the best combination separates the functional and non-functional MREs with high accuracy (mean AUC = 0.931), as visualized in principal component space in Figure 3D. Each MRE can be considered as a point in multi-dimensions, with each axis as the enrichment level for a mark; to show the data in two-dimensions, we define new axes, called principal components, which are combinations of the original variables satisfying certain desirable properties. We can indeed observe a good separation of the functional from non-functional MREs in this view (Figure 3D).

Genome-wide prediction of functional MREs

The analyses presented so far focused on only a subset of clearly functional and non-functional MREs. This allowed us to effectively identify chromatin features that can distinguish functional MREs from non-functional ones, and to build a predictive SVM model for functional MREs. Here we extend our analysis to test whether our model could accurately select additional functional MREs genome-wide. We trained an SVM model with Kc cell chromatin features and then tested its ability to eliminate non-functional MREs on autosomes and chromosome X using S2 data. The SVM algorithm selects the decision threshold that optimally separates functional from non-functional MREs, as confirmed in Figure S3E, and the overall AUC of this prediction is about 0.84 (Figure S3F). We specifically tested different individual and combinations of features. Using the best combination of features, our SVM model can eliminate over 75% of candidate MRE sites on X, and ~85% of candidate sites on autosomes, while retaining almost all of the functional MREs on the X chromosome (up to 94%) (Table S2). Almost 10,000 non-functional sites are eliminated using our model, with retention of approximately 1600 MREs genome-wide. Approximately half (763) of those remaining MREs map to the X chromosome but are not included in the conservative set of 137 CES.

We suspect that the large number of remaining MREs on the X chromosome indicates that there may be more true MSL binding sites than the set of 137 CES we used in this study. Therefore, we asked how many of these additional 763 MREs overlap with previously mapped MSL binding sites identified by MSL3 ChIP-seq [8]. Of the 763 SVM-predicted functional MREs on X, 503 overlapped with an MSL binding site (Figure 3E). This suggests that the actual false positive rate on the X chromosome may be as low as 260/3343 = 7.8%. This is slightly lower than the false positive rates for the autosomes (893/8144 = 11%) (Table S2), likely due to the fact that even though most strong peaks identified in the MSL3 ChIP-seq data with stringent criteria are CES [8], some may be sites to which MSL complex spreads.

Increased lability of nucleosomes at chromatin entry sites correlates with MSL binding

In addition to enrichment for marks associated with active genes, we also saw relative depletion of histone H1 over functional MREs (Figure 1), and, from previous work, depletion of H3 and thus presumably nucleosomes themselves [8,10]. Therefore, we examined modENCODE data from S2 and Kc cells on the release of nucleosomes following salt extraction to determine whether functional MREs are packaged into more labile chromatin when compared to non-utilized MREs [34]. We found that in male S2 cells functional MREs are depleted for histones in general, and
enriched for nucleosomes that are extracted in low salt or remain in the pellet after high salt extraction (Figure 4), both fractions that were previously characterized as enriched in regulatory regions [35]. In addition, the two sets of non-functional MREs on the X chromosome appeared to have a milder, but discernable increase in nucleosome lability when compared to the MREs on autosomes, consistent with the observation that X chromosome in male S2 cells generally adopts a more open chromatin conformation [36].

In contrast, CES MREs in female Kc cells exhibit a modest average decrease in nucleosomal occupancy (Figure 4), but intriguingly, this appears to be a difference at a subset of sites rather than the entire set (Figure S4). Notably, the entire X chromosome in Kc cells does not appear to be packaged in a more open chromatin state compared to autosomes (Figure 4). We conclude that strong nucleosome depletion and a more open chromatin conformation on X are mainly consequences rather than causes of MSL binding.

JIL-1 kinase enrichment and histone H1 depletion on active gene bodies of the MSL–bound X chromosome

Once MSL complex identifies the male X, we have proposed that it spreads to affect the active genes on the chromosome as a whole [5]. In addition to the core MSL complex consisting of proteins that are essential in males but not females (MSL1, MSL2, MSL3, MOF, and MLE), the JIL-1 kinase is known to be enriched on the male X [37]. JIL-1 is essential in both males and females and binds interband regions on all chromosomes in both sexes [38]. Since we observed that JIL-1 is enriched at functional MREs (Figure 1 and Figure 3A), we tested whether it is also associated with active gene bodies. We constructed average scaled profiles of JIL-1 binding (meta-gene profiles) of all genes greater than 2 kb in length based on the FlyBase dm3 gene annotation [39]. Gene expression in the three cell lines was determined by RNA-seq data (Figure 5) [34]. We found that JIL-1 binds active gene bodies, with a bias towards 3' ends, on all chromosome arms (Figure 5A). On the male X, this pattern is increased in its intensity above the level on autosomes and correlates strongly with binding of the MSL complex since the increased occupancy is not seen on female X chromosomes (Figure 5B). These results are consistent with previous polytene immunostaining [37] and ChIP analyses [40].

In contrast to JIL-1, the linker histone H1 shows depletion on active genes (Figure 5C). Interestingly, in male cells this depletion is more prominent on X-linked gene bodies than on autosomal gene bodies, whereas X and autosomes show no obvious difference in female cells (Figure 5D), consistent with previous polytene immunostaining results [41]. These two results further underscore the distinct character of the Drosophila male X chromosome once MSL complex is bound to active genes.

When examining our modENCODE data, we noticed that many additional data sets are slightly enriched on the entire X chromosome compared to autosomes in male S2 cells, but not in female Kc cells (Figure S6, and Table S3). X-chromosome-wide enrichment of nucleoporins, Megator and Nup153 have also been observed in male S2 cells, but not in female Kc cells [42]. These

---

**Figure 4.** Increased lability of nucleosomes at chromatin entry sites correlates with MSL binding. Average enrichment profiles of chromatin properties around MREs are shown for S2 and Kc cells. Nucleosome density and successive salt extracted fractions of MNase-treated chromatin from S2 and Kc cells were described previously [28]. Profiled chromatin properties comprise nucleosome density (black) and successive salt extracted fractions of MNase-treated chromatin: low salt (pink, 80 mM NaCl), high salt (blue, 600 mM NaCl), and pellet (green, salt insoluble). The dashed red lines on each plot indicate the MRE centers. In male S2 cells, nucleosomes are more labile at the MREs on the X chromosome in general, and nucleosome density is especially low at functional MREs. The relative lability of nucleosomes on the X chromosome is not seen in female Kc cells, and the extent of nucleosome depletion at functional MREs is less pronounced. See also Figure S4.

doi:10.1371/journal.pgen.1002646.g004
results are unlikely to simply reflect increased access of antibodies to X chromatin in the ChIP procedure, because histone H1 shows the opposite trend. Therefore, these enrichments may be related to dosage compensation of the male X, either directly, as is the case for H4K16ac, JIL-1, and possibly RNA pol II, or indirectly, as a consequence of the more open chromatin environment created by the dosage compensation mechanism.

MSL1 and H4K16 acetylation are found on virtually all active X linked genes in male cells

MSL-dependent dosage compensation is thought to be an organism-wide phenomenon in Drosophila males, excluded from the germline [43], but otherwise not restricted to particular tissues or developmental time points. Classical mitotic recombination experiments support a requirement for MSL proteins throughout development in dividing tissues [44]. In addition, comparison of gene expression in males and females demonstrates that the vast majority of X-linked genes are up-regulated in males [45]. However, stable MSL binding appears to be more restricted than its functional consequence, H4K16 acetylation [22], so we wondered whether binding favored particular types of genes. To examine this, we plotted the chromatin marks and MSL binding along active X linked genes in S2 cells (Figure 6). We found that MSL1 and H4K16 acetylation cover the vast majority (86%) of active X linked genes. Apparent exceptions (green cluster) are interesting as those genes also lack H3K36me3 (Figure 6) and H2B-ubiquitin (data not shown), two prominent marks of transcription [18].

While MSL1 and H4K16ac are associated with the bodies of virtually all active X linked genes in male S2 cells, the MOF H4K16 histone acetyltransferase was notably absent from a subset (dark brown cluster at bottom of Figure 6). Most of these genes still showed limited MOF enrichment around the promoter region, but not within the gene bodies as is characteristic of MSL complex. We were unable to identify any feature, such as relative expression level or chromatin state, that would distinguish these genes from the genes that showed MOF enrichment.

Since functional MSL chromatin entry sites are also preferentially associated with active gene marks, we asked where CES map relative to the set of clustered genes on X, indicating the location of CES by red dots on the gene structures in Figure 6 (H3K36me3 column). Our results demonstrate that CES are located at variable positions relative to active genes, with a bias towards their 3′-ends. Interestingly, the subset of genes lacking strong MOF binding within gene bodies also lack nearby entry sites, in agreement with the observation that MSL binding is strongest in the close vicinity of mapped chromatin entry sites [10,46].

Figure 5. The bodies of active X-linked genes are enriched for JIL-1 kinase and depleted for histone H1 in S2 but not Kc cell lines. Each panel shows the average scaled ChIP enrichment profile (meta-gene profile) of active and inactive genes located on X chromosome and autosomes. (A) JIL-1 in S2 cells, (B) JIL-1 in Kc cells, (C) H1 in S2 cells, and (D) H1 in Kc cells. Notably, JIL-1 is enriched along the gene bodies of X-linked genes in males, while histone H1 is depleted. See also Figure S5. doi:10.1371/journal.pgen.1002646.g005
Discussion

Genetic, genomic, and biochemical analyses in eukaryotes have revealed that DNA binding motifs alone are insufficient to explain the selective occupancy or specificity of regulatory factor function [16,17]. The number of predicted binding sites is often vastly greater than the number of sites actually utilized. Therefore, a very important question in transcriptional regulation is how to identify additional parameters that must govern accurate binding site selection.

In this study, we considered the roles of chromatin environment and flanking sequence composition in selection of functional binding sites by a sequence-specific protein complex. It is generally not clear whether the chromatin features that are often observed at the binding sites of proteins contribute directly to binding selectivity or are simply a consequence of binding. In the dosage compensation system of the X chromosome in *Drosophila*, we had a unique opportunity to address this question because we can compare the chromatin environment of MSL binding sites in female cells, in the absence of the complex, to male cells, where the functional sites are bound. We also utilized binding data from an RNAi experiment in which we knocked down a component of the sex determination pathway in females to induce dosage compensation. Our bioinformatic analysis of a large number of profiles from the modENCODE project suggests that a pre-existing active chromatin context plays a critical role in establishing the initial binding of the MSL complex on the X. We also made the surprising discovery that GC content in the DNA surrounding functional binding sites has a characteristic profile.

In summary, our results strongly support a model in which an active chromatin composition helps define the initial entry sites selected by the MSL complex (Figure 7). Functional MSL binding results in increased lability of local nucleosomal composition, and H4K16 acetylation and JIL-1 binding along the bodies of virtually all active X-linked genes. Our work provides key insights into the order of events leading to dosage compensation in *Drosophila*, and can also serve as a model for using genome-wide data sets to understand how sequence-specific factors find their ultimate targets.

**Materials and Methods**

modENCODE ChIP-chip data processing

The majority of the ChIP-chip data are from the modENCODE project [18]. Genomic DNA Tiling Arrays v2.0 (Affymetrix) were used to hybridize both ChIP and input DNA. We obtained the log-intensity ratio values (M-values) for all perfect match (PM) probes: $M = \log_2(\text{ChIP intensity}) - \log_2(\text{input intensity})$.
and performed a whole-genome baseline shift so that the mean of \( M \) in each microarray is equal to 0. The smoothed log intensity ratios were calculated using LOWESS with a smoothing span corresponding to 500 bp, combining normalized data from two replicate experiments. All data are publicly accessible online through the modENCODE project (URL listed in Table S1). Data analysis was performed in R statistical programming environment. For the visualization of the heatmap (e.g., Figure 1), the \(+/-5\) kb region surrounding each MRE was separated into non-overlapping bins of 200 bp. The smoothed probe value within each bin is averaged to obtain the enrichment value for that bin.

**Local sequence GC content**

The GC content around each nucleotide is defined as the proportion of G or C in the closest 101 bp (i.e., the target nucleotide, 50 bp upstream and 50 bp downstream). Similar to the ChiP-chip data, we separated the \(+/-5\) kb region surrounding each MRE into non-overlapping bins of 200 bp. The average GC content in each bin represents the average of the GC content of the 200 bp within that bin.

**RNAi followed by expression analysis and ChiP–chip**

We generated double-stranded RNA (dsRNA) to target GFP (negative control) or \( S\alpha \) transcripts (amplicons designed by the Drosophila RNAi Screening Center [www.flyrnai.org], as described previously [22]). The following primer sets were utilized to amplify PCR products to template dsRNA synthesis:

**GFP**

\[
\begin{align*}
F & \quad 5'-\text{TATACGACTCTATAGGGAGATCTTGAAAGCT-3'} \\
R & \quad 5'-\text{TAATACGACTCTATAGGGAGATCTTGAAAGCT-3'}
\end{align*}
\]

\( \text{H4K16ac} \)

\[
\begin{align*}
\downarrow & \quad \text{Nucleosome occupancy} \\
\uparrow & \quad \text{H4K16ac}
\end{align*}
\]

Dosage compensation

**Kc**

\begin{center}
\begin{tabular}{ccc}
\hline
 & MRE & MRE \\
\hline
ChrX & & \\
\hline
\end{tabular}
\end{center}

Kc

\[\text{MRE}\]

\[\text{ChrX}\]

\[\text{MRE}\]

\[\text{ChrX}\]

**S2 or BG3**

\begin{center}
\begin{tabular}{ccc}
\hline
 & MRE & MRE \\
\hline
ChrX & & \\
\hline
\end{tabular}
\end{center}

Functional MRE

Non-functional MRE

\[\text{= active chromatin}\]

\( \uparrow \text{GC in flanking region (e.g., H3K36me3)} \)

Figure 7. Model for binding site selection by a chromatin associated factor. Our results support roles for local chromatin environment and flanking GC content in discrimination of true target sites of the MSL dosage compensation complex. The model depicts the GC content and active chromatin marks surrounding MREs in female Kc cells that predict binding by MSL complex in male S2 or BG3 cells (or after MSL induction in female Kc cells). MREs that do not pre-exist in a favorable environment are not bound by MSL complex and thus are non-functional. Definition of the favorable chromatin features that pre-exist factor binding may be a general tool, in addition to DNA motif analysis, for prediction of functional binding sites.

doi:10.1371/journal.pgen.1002646.g007

Cross-validation

We used 10-fold cross-validation to estimate the predictive power of a classification model based on a training dataset (e.g., chromatin feature in Kc cells) and a test dataset (e.g., chromatin feature in S2 cells). Each sample in a dataset is an MRE, a feature is a histone modification (e.g., H3K36me3) or a chromatin binding protein (RNA Pol II), and the label for each sample is either “Functional MRE” (positive class) or “Non-functional MRE”
Construction of meta-gene profiles

RNA–seq gene expression data

Support vector machine (SVM)

Calculation and visualization of the ROC curves were performed standard deviation of the 10 AUC values are recorded. AUC is calculated for each fold (one iteration), and the mean and predictor achieves an AUC of 1. Using 10-fold cross-validation, an model. A random predictor receives an AUC of 0.5, and a perfect predictor achieves an AUC of 1. Using 10-fold cross-validation, an AUC is calculated for each fold (one iteration), and the mean and standard deviation of the 10 AUC values are recorded. Calculation and visualization of the ROC curves were performed by the ROCR package [32].

Support vector machine (SVM)

SVM is a supervised classification algorithm that separates two classes of data based on a set of features [30,31]. In this study, the set of ChIP enrichment at each MRE is treated as a feature vector of that MRE. Given a set of feature vectors from functional MREs and a set of feature vector from non-functional MREs, the SVM algorithm calculates an optimally-separating hyperplane by maximizing the distance (called margin) between the hyperplane and the nearest points from the two classes. This hyperplane effectively divides the space of feature vectors into two regions, one for each class, with the idea that the larger margin lowers the error of the classifier. To make a prediction, the feature vector corresponding to a MRE from the test set is compared to this hyperplane to determine on which side of the separating boundary this sample is located. We used the SVM implementation in the R package e1071, which is optimized for the radial basis function kernel and uses an Sequential Minimal Optimization-type algorithm [48] using default parameters for training the SVM.

ChIP–seq data processing

We used the MSLe3-TAP ChIP-seq data from Alekseyenko et al [8]. The raw sequence reads were aligned to the Drosophila melanogaster genome assembly dm3 using bowtie with default options [49]. We only allowed uniquely mapped reads to be reported. This procedure resulted in 2.8 and 2.4 million mapped reads for ChIP and input DNA samples. The aligned reads were then analyzed with SPP [50] to identify ChIP-enriched regions (FDR threshold of 0.05).

RNA–seq gene expression data

Gene expression level estimates in S2, BG3 and Kc cells were obtained from the modENCODE project [34]. The expression of each gene is quantified in terms of RPKM (reads per million reads per kilobase). The distribution of gene expression in each cell line was assessed and a cut-off of RPKM = 3 was determined to be a good threshold to separate active vs. inactive genes (Figure S5A). This definition of active vs. inactive genes was used in the construction of meta-gene profiles.

Construction of meta-gene profiles

We used the gene annotation from FlyBase [39] to define transcription start and end sites (TSS and TES respectively). We only included genes with a minimum length of 2 kb (7,231 of 15,186 genes) to exclude short genes from our analysis. The ChIP enrichment in the 2 kb region centered on the TSS and TES, as well as the ChIP enrichment within the gene body scaled to 1 kb, were calculated and averaged for the active and inactive genes in X and autosomes. The definitions of active vs. inactive genes were defined by RNA-seq data.

Accession numbers

All ChIP-chip and RNA-seq data are available from mod-ENCODE, and the URL for individual datasets is listed in Table S1. The ChIP-chip and microarray gene expression data pertaining to the Sxl RNAi experiments are accessible from GEO (Accession number: GSE34859).

Supporting Information

Figure S1 Distribution of functional and non-functional MREs. (A) The number of MREs per megabase (Mb) on each major chromosome arm based on motif detection with different p-value thresholds. The number of MREs located on the X chromosome is roughly twice the number of each autosomal chromosome arm. (B) The distribution of motif detection p-values for each of the classes of MREs defined in this study. The motif specificity (as approximated by motif detection p-value) of the functional MREs at chromatin entry sites (CESs) is similar to other random MREs on chromosome X and an autosomal arm (chr2L). (C) Histograms showing the distance between consecutive randomly chosen 137 non-functional MREs (left panel) and 137 functional MREs (right panel) along the X chromosome. The red dotted lines indicate the average log2 distance in base pairs between two consecutive MREs. The mean distances of the functional and non-functional MREs are not significantly different (t-test), suggesting there is no significant difference in the distribution and clustering of functional and non-functional MREs. (DOC)

Figure S2 Average GC content around different classes of MREs. (A) The average plot of GC content around chromatin entry site (CES), autosomal MREs that have H3K36me3 enrichment, and MREs randomly chosen from chromosome 2L. (B) Heat maps showing the distribution of GC content for the MREs shown in panel A. It is particularly striking to observe that even though GC content is generally higher at functional MREs and non-functional autosomal MREs enriched for H3K36me3, there is a strong decrease in GC content only at the center of functional MREs. (DOC)

Figure S3 Chromatin features are predictive of functional MREs in both male and female cells. (A–B) AUC of individual and all possible combinations of chromatin features for predicting functional MREs based on 10-fold cross-validation. For each feature or feature set, an SVM model was trained on the chromatin ChIP-chip data of Kc cells, and the prediction performance was tested on data from S2 and BG3 cells. H3K36me3 and JIL-1 are the best individual features, and the best SVM prediction models use a combination of 4 or 5 features. The AUC of the best individual, best combination, or all features are shown in brackets. (C) Correlation between every pair of features using the Kc cells data. (D) ROC curves showing the ability of various chromatin features to discriminate functional MREs from non-functional MREs based on 10-fold cross-validation, where SVM was trained on Kc cells, and the performance was assessed on data from BG3 cells. (E) The
trade-off between retention of CES and elimination of non-functional autosomal MREs when using SVM for genome-wide prediction of functional MREs. After we train an SVM, we can use different thresholds (distance to hyperplane) to determine whether an MRE is functional or not. The default threshold is 0 (i.e., the best binary classification is achieved using the SVM-determined hyperplane). (F) The trade-off between true positive rate (defined as proportion of CES retained) and false positive rate (defined as proportion of autosomal MRE retained) can be visualized as an ROC curve. The AUC is about 0.84.

(FIGURE S4) Decreased nucleosome occupancy upon MSL binding on X chromosome. (A) The average nucleosome occupancy in functional and non-functional MREs in male S2 cells. There is a strong decrease of nucleosome occupancy in functional MREs on the X chromosome. (B) The average nucleosome occupancy in functional and non-functional MREs in female Kc cells. There is a less pronounced difference in nucleosome occupancy among different classes of MREs. Collectively, these observations suggest that decrease in nucleosome occupancy is mainly a result of MSL binding on the X chromosome.

(FIGURE S5) Estimating gene expression activity in S2, BG3 and Kc cells using RNA-seq, and additional meta-gene profiles. (A) Distribution of normalized read counts (RPKM) in S2, BG3 and Kc cell lines. A bimodal distribution of gene expression is apparent. A threshold of log2(RPKM+1)=2 (i.e., RPKM = 3) was chosen as a threshold to distinguish active from inactive genes (red dotted lines). (B) Meta-gene profiles of JIL-1 and H1 in active and inactive genes of BG3 cells. (C) Meta-gene profiles of H4K16ac in active and inactive genes of S2 and Kc cells.

(FIGURE S6) Chromosome-wide enrichment of different histone marks. There is generally no significant difference between the enrichment distribution on chromosome X and the autosomes in female Kc cells. However, there is enrichment of H2B-ubiq and H3K36me3 and depletion of H1 and H4 in the male S2 and BG3 cell lines, suggesting X chromosome specific enrichment of certain active histone marks in male cells upon dosage compensation. See also Table S2.